Introduction: Addressing Colorectal Cancer Screening Demand, Polyp Recurrence Risk, and Endoscopic Resection Efficiency
For gastroenterologists, endoscopists, and colorectal cancer (CRC) screening program directors, polypectomy—the endoscopic removal of colorectal polyps (adenomas, serrated lesions)—is the cornerstone of CRC prevention. The adenoma-carcinoma sequence (normal mucosa → adenoma → dysplasia → carcinoma) takes 5–10 years, providing a window for screening and polypectomy to reduce CRC incidence (40–60% reduction) and mortality (50% reduction). Polypectomy snares—metal loops passed through the endoscope working channel—encircle the polyp base and, with electrocautery (hot snare) or without (cold snare), cut and coagulate to remove tissue safely. As CRC screening programs expand globally (US 45–75 years, EU 50–74 years, China 50–74 years), and colonoscopy volume increases (20M+ colonoscopies annually in US, 15M+ in EU, 30M+ in China), demand for polypectomy snares is growing. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Polypectomy Snare for Endoscopic Polypectomy – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Polypectomy Snare for Endoscopic Polypectomy market, including market size, share, demand, industry development status, and forecasts for the next few years.
For hospital endoscopy unit directors, gastroenterology department heads, and surgical procurement managers, the core pain points include achieving complete polyp resection (R0) to prevent local recurrence (2–10% for piecemeal resection), minimizing complications (bleeding 1–5%, perforation 0.1–0.5%, post-polypectomy syndrome), and maximizing adenoma detection rate (ADR, 25–40% for screening colonoscopy). According to QYResearch, the global polypectomy snare market was valued at US$ 334 million in 2025 and is projected to reach US$ 534 million by 2032, growing at a CAGR of 7.0% . In 2024, global production reached approximately 3.18 million units, with an average unit price of US$ 100.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095745/polypectomy-snare-for-endoscopic-polypectomy
Market Definition and Core Capabilities
Polypectomy snare for endoscopic polypectomy is a medical device introduced through the endoscope working channel to excise polyps and lesions in the gastrointestinal tract. Core capabilities:
- Polypectomy Technique: Cold snare polypectomy (CSP) – no electrocautery, for small polyps (<10mm), lower bleeding risk, faster (no waiting for coagulation), lower complication rate (post-polypectomy syndrome, delayed bleeding). Hot snare polypectomy (HSP) – electrocautery (cut/coagulation blend), for larger polyps (10–20mm), higher bleeding risk but complete resection (en bloc) and hemostasis.
- Snare Sizes: Small (10–15mm) – small polyps (<10mm), cold snare preferred. Medium (20–25mm) – medium polyps (10–20mm), hot snare for en bloc resection (if possible) or piecemeal for larger. Large (>30mm) – large polyps (>20mm), piecemeal resection (hot snare, often EMR with submucosal injection).
- Snare Shapes: Oval (standard), hexagonal (better grip), rotatable (improves positioning), braided (increased stiffness, better cutting), round (flexible). Cold snares have thinner wire (<0.3mm) to reduce tissue trauma; hot snares have thicker wire (0.4–0.6mm) for electrocautery.
Market Segmentation by Snare Size
- Small (10-15mm) (40–45% of revenue, largest segment): For small polyps (<10mm), cold snare polypectomy (CSP) – lower bleeding risk, faster, no electrocautery (no post-polypectomy syndrome). Used in high-volume screening colonoscopy (polyps found in 25–40% of exams). Lower cost ($50–100). Dominant in colorectal cancer screening.
- Medium (20-25mm) (30–35% of revenue): For medium polyps (10–20mm), hot snare polypectomy (HSP) for en bloc resection if pedunculated or favorable morphology (Paris classification). Piecemeal resection if sessile or large. Higher cost ($100–200).
- Large (>30mm) (20–25% of revenue, fastest-growing at 7–8% CAGR): For large polyps (>20mm), piecemeal resection (EMR – endoscopic mucosal resection) with submucosal injection (lifting). Requires larger snares (≥30mm), often rotatable or braided for better grip. Higher cost ($200–500). Used in advanced endoscopy (tertiary referral centers, academic medical centers).
Market Segmentation by Facility Type
- Hospital (70–75% of revenue, largest segment): Inpatient and outpatient colonoscopy. Complex polyps (large, sessile, laterally spreading tumors – LST), piecemeal EMR, advanced techniques (underwater EMR, endoscopic submucosal dissection – ESD). High-volume academic centers, community hospitals, and referral centers. Full range of snare sizes (small, medium, large). Dominant setting for polypectomy due to complication management (bleeding, perforation).
- Ambulatory Surgery Centers (ASCs) (20–25% of revenue, fastest-growing at 8–9% CAGR): Outpatient colonoscopy (same-day discharge) for screening and surveillance. Simple polyps (<10mm, cold snare). Lower complexity, lower complication risk, higher throughput. ASCs require efficient, cost-effective snares (small, cold snare). Growing shift from hospital to ASC colonoscopy (cost containment, patient preference).
- Other (5–10% of revenue): Office-based endoscopy (private practice), rural hospitals, and mobile endoscopy units.
Technical Challenges and Industry Innovation
The industry faces four critical hurdles. Incomplete resection & polyp recurrence – piecemeal resection (large polyps) leaves residual tissue (2–10% recurrence at 6–12 months). Cold snare for small polyps (<10mm) has lower incomplete resection rate (1–5%) vs. hot snare (5–10%). EMR with submucosal injection improves complete resection (en bloc for polyps <20mm). Bleeding complications – immediate bleeding (during procedure) managed by snare tip coagulation, hemostatic clips. Delayed bleeding (hours to days post-procedure) more common with hot snare (1–5%) vs. cold snare (<1%). Anticoagulant/antiplatelet management (hold or bridge) affects bleeding risk. Perforation risk – deep mural injury (muscularis propria) during snare resection (0.1–0.5%). Risk factors: large polyp (>20mm), thin wall (right colon, cecum), electrocautery (thermal injury). Clip closure of defect reduces perforation risk. Polyp retrieval & histopathology – retrieved polyps sent for histopathology (adenoma, serrated lesion, cancer). Incomplete retrieval (lost in lumen) affects diagnosis and surveillance intervals (3–10 years). Suction traps, retrieval nets, and careful technique improve retrieval rate.
独家观察: ASC Outpatient Colonoscopy Fastest-Growing Segment
An original observation from this analysis is the double-digit growth (8–9% CAGR) of ambulatory surgery center (ASC) colonoscopy and polypectomy, outpacing hospital-based procedures (6–7% CAGR). Outpatient colonoscopy for screening (average-risk 45–75 years) and surveillance (prior polyps) reduces healthcare costs (50–70% lower than hospital), improves patient satisfaction (same-day discharge), and increases procedure volume (higher throughput). ASCs require efficient, cost-effective cold snares (small polyps <10mm) for high-volume screening. Major polypectomy snare manufacturers (Boston Scientific, Olympus, Cook Medical, Medtronic) are developing ASC-specific product lines (cold snares, single-use, rapid deployment). ASC polypectomy segment projected 30%+ of procedure volume by 2030 (vs. 20% in 2025). Additionally, cold snare polypectomy (CSP) for small polyps (<10mm) is becoming standard of care (lower bleeding, no electrocautery, faster) vs. hot snare (higher bleeding, post-polypectomy syndrome). CSP adoption (80–90% of small polyps in US/EU) reduces snare cost (no electrosurgical generator, simpler device). Cold snare segment growing 8–9% CAGR.
Strategic Outlook for Industry Stakeholders
For CEOs, product line managers, and medical device investors, the polypectomy snare market represents a high-growth (7.0% CAGR), procedure-driven opportunity anchored by colorectal cancer screening expansion, outpatient ASC colonoscopy growth, and cold snare adoption. Key strategies include:
- Investment in cold snares optimized for ASC colonoscopy (thin wire, rapid deployment, reliable loop opening/closing) for high-volume screening (small polyps <10mm).
- Development of large snares (≥30mm) for EMR of large polyps (>20mm) with enhanced grip (braided, rotatable), submucosal injection compatibility, and piecemeal resection efficiency.
- Expansion into single-use snares (infection prevention, no reprocessing) for ASCs and high-risk patients (immunocompromised, known CRE carriers).
- Geographic expansion into Asia-Pacific (China, India, Southeast Asia) for rising colonoscopy volume (CRC screening programs) and North America/Europe for ASC outpatient shift.
Companies that successfully combine complete resection (R0), low complication rate (bleeding, perforation), and cost-effective ASC snares will capture share in a $534 million market by 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
